NEW YORK/LONDON, Dec 3 (Reuters) - Johnson & Johnson JNJ.N, the U.S.-based healthcare company, has hired Goldman Sachs GS.N to explore a sale of its artificial sweetener brand Splenda, sources familiar with the matter told Reuters.
The process is still at an early stage, with prospective buyers currently signing non disclosure agreements, one of the sources said, speaking on condition of anonymity because the matter is private.
J&J declined to comment. Goldman Sachs was not immediately available.